Yourgene Health PLC (LSE:YGEN) - Share price


Stock Report

Yourgene Health PLC YGEN

Last Price
GBX12.51

Day Change
-0.24|-1.88%

As of 30/11/2021
08:05:34 GMT | GBX
Minimum 15 Minutes Delay.

Last Close12.75p
Day Range12.51 - 12.51
Mkt Cap92.28Mil
52-Wk Range11.50 - 18.00
Yield %-
ISINGB00BN31ZD89
Volume6,450
P/E11.39
P/S0.05
P/CF-0.24

Share Price

Total Returns 29/11/2021

 Chg (%)  
More ...
Yourgene Health PLC-3.77 
FTSE 100 TR GBP-1.47
 
Financials
201920202021
More ...
Income Statement
Turnover8.8816.6118.29
Operating Profit-4.78-2.44-6.25
Net Profit3.39-2.43-12.18
Reported EPS0.90-0.40-1.80
Balance Sheet
Current Assets5.3010.0015.73
Non Current Assets10.3027.6833.39
Total Assets15.6037.6849.13
Current Liabilities4.256.478.77
Total Liabilities4.9011.3816.20
Total Equity10.7026.3032.92
Cash Flow
Operating Cash Flow-4.04-2.06-4.12
Net Change in Cash0.971.514.23

Regulatory News

DateAuthor Headline
19/07/2019James Gard FTSE 100 Miners Ride the Iron Ore Boom
An iron price boom has helped swell the coffers of the likes of BHP, Rio and Anglo, but can their recent strong run be sustained if China is slowing down?
14/05/2019Holly Black Top Investment Trusts for Income
Investing in trusts can pay dividends - but make sure the pay-out is sustainable
02/02/2017Emma Simon Investor Views: "My Best Returns Have Been from Emerging Markets"
Investment analyst Laith Khalaf tells Morningstar how he manages his own personal portfolio for long-term growth
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
09/02/2021PurchaseDr. John Robert Brown12.20102,45012,499.00

Company Profile

Yourgene Health PLC is a molecular diagnostics company. The company develops and commercializes genetic products and services. It has developed the IONA test which is an advanced non-invasive prenatal screening test for Trisomy 21, 18 and 13. The Sage prenatal screen which is an advanced non-invasive prenatal screening solution using the latest developments in DNA technology to detect placental DNA in maternal blood. Its operating segment includes Genomic Technologies and Genomic Services. The company generates maximum revenue from Genomic Technologies segment.

Sector

Diagnostics & Research

Index

FTSE AIM All-Share

Next Event 17/12/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-29.01
Op Mrgn-0.34
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, Senior Independent DirectorDr. John Robert Brown
Non-Executive Director, ChairmanMr. Adam Reynolds
Executive Director, Chief Financial Officer and Company SecretaryMr. Barry Kenneth Hextall
Non-Executive DirectorMr. Nicholas Mustoe
Executive Director, Vice ChairmanDr. Stephen Little
Executive Director, Chief Operating OfficerMr. Hayden Jeffreys
Executive Director, Chief EntrepreneurDr. Chia-Han Bill Chang
Executive Director, Chief Executive OfficerMr. Lyn Dafydd Rees
Non-Executive DirectorMr. Jonathan Seaton
Executive Director, Chief Scientific OfficerDr. Joanne Mason
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.